Gujarat Themis Biosyn's Credit Rating Placed on Watch with Negative Implications
Gujarat Themis Biosyn's bank facilities are on Rating Watch with Negative Implications due to significant acquisition plans totaling ~₹3,000 crore. The company aims to fund these via a ₹1,000 crore QIP. Acquisitions include MBJ for ¥1.5 Billion (~₹1,300 crore) and Sanofi brands for €158 million (~₹1,700 crore). GTBL disputes the rating, citing ongoing QIP and future revenue growth.
A 'Rating Watch with Negative Implications' can affect the company's borrowing costs, investor confidence, and future access to capital, thereby having a significant impact on its operations and financial strategy.
The credit rating has been placed on 'Rating Watch with Negative Implications' due to concerns over the company's large acquisition plans and funding uncertainty, indicating a potentially negative outlook.
Gujarat Themis Biosyn Limited (GTBL) has had its long-term and short-term bank facilities placed on Rating Watch with Negative Implications by CARE Ratings Limited. This action is primarily due to the company's significant acquisition plans, which include acquiring 100% equity in MicroBiopharm Japan Co., Limited (MBJ) for ¥1.5 Billion (~₹1,300 crore) and a portfolio of anti-tuberculosis and anti-infective brands from Sanofi for €158 million (~₹1,700 crore). The rating watch reflects concerns over the scale of these acquisitions, which are approximately 10 times the company's tangible net worth, and the uncertainty surrounding their funding structure. GTBL plans to raise ₹1,000 crore through a Qualified Institutional Placement (QIP), the timely completion of which is considered critical for the MBJ acquisition.
The company has also made significant capital expenditures, including enhancing fermentation capacities and setting up a hybrid power generation unit. The PBILDT margin remained healthy between 45% and 50% for the five years ending FY26, stabilizing at 46.01% in FY26. The company expects its operating margins to improve with the solar power plant project nearing completion in Q2FY27. However, the overall gearing moderated to 0.56x as of March 31, 2026, from 0.12x a year prior, due to increased term loans and working capital borrowings.
GTBL has formally expressed its dissent and non-acceptance of the rating, stating that the agency's decision is overly backward-looking and fails to reflect concrete de-risking of liquidity and the ongoing QIP funding roadshows. The company argues that the leverage increase will be an artifact of global acquisitions adding to revenue and EBITDA multiples and that the agency is evaluating debt obligations that do not yet exist against the current revenue base.
GTBL's scale of operations remains moderate, with Total Operating Income (TOI) reported at ₹167.23 crore in FY26, an increase of 9.81% year-on-year. Operations continue to be working capital intensive, with a higher gross current assets period of 205 days in FY26. The company has completed the forward integration of API manufacturing capex and trial production has started. The hybrid power generation capex is also nearing completion, with expected go-live from August 2026.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.